查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584134

肺腺癌治疗市场，按药物类别、治疗类型、治疗阶段、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Lung Adenocarcinoma Treatment Market, By Drug Class, By Therapy Type, By Stage of Treatment, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年肺腺癌治疗市场规模为55,1209万美元，2024年至2032年复合年增长率为10.70%。

肺腺癌治疗市场-市场动态

吸烟率上升推动肺腺癌治疗市场的成长

全球吸烟率不断上升，大大促进了肺腺癌治疗市场的成长，因为吸烟是肺癌的主要危险因子。世界卫生组织 (WHO) 估计，目前有超过 13 亿人吸烟，全球癌症相关死亡中近 22% 是由烟草使用造成的。在美国，疾病管制与预防中心 (CDC) 报告称，肺癌是癌症死亡的主要原因，其中约 85% 的病例是由吸烟引起的。随着公众意识活动的加强和戒烟计画的实施，对有效治疗的需求预计将会增加。製药公司正在透过投资创新疗法（包括标靶治疗和免疫疗法）来应对这一趋势，以应对不断增长的患者群体。此外，美国肺臟协会等组织的措施旨在减少吸烟率并改善早期诊断，进一步推动肺腺癌领域对先进治疗方案的需求。

肺腺癌治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 10.70% 左右的复合年增长率成长

根据药物类别细分，预计 EGFR 抑制剂将在 2023 年呈现最大市场份额

从治疗类型细分来看，2023年标靶治疗为主导类型

根据治疗阶段细分，晚期或转移性腺癌是 2023 年的主要类型

按地区划分，北美是 2023 年的主要收入来源

肺腺癌治疗市场-細項分析：

全球肺腺癌治疗市场根据药物类别、治疗类型、治疗阶段、最终用户和地区进行细分。

根据药物类别，市场分为四类：EGFR抑制剂、ALK抑制剂、PD-1/PD-L1抑制剂和VEGF抑制剂。 EGFR 抑制剂因其针对特定突变的有效性而具有最高优先顺序。 ALK 抑制剂紧随其后，为 ALK 阳性患者提供标靶治疗，而 PD-1/PD-L1 抑制剂和 VEGF 抑制剂则提供了额外的治疗选择。

根据治疗类型，市场分为四类：化疗、标靶治疗、免疫治疗和合併治疗。标靶治疗因其在解决特定癌症突变方面的精确性而排名最高。接下来是免疫疗法，利用免疫系统对抗癌症。联合治疗越来越受到关注，而化疗仍然是标准但不太优先的选择。

肺腺癌治疗市场 - 地理洞察

北美是肺腺癌治疗市场的领先地区，这主要是由于肺癌的高发病率和先进的医疗基础设施。根据美国癌症协会预测，2023年，肺癌预计将占美国所有癌症死亡的25%左右。抗（ipilimumab）的新联合疗法用于患者晚期肺腺癌，突显了治疗方案的持续创新。欧洲紧随其后，德国和英国等国家增加了对肺癌研究和个人化医疗方法的投资。欧洲肿瘤内科学会 (ESMO) 报告称，在旨在早期检测和预防的措施的支持下，越来越重视标靶治疗。同时，由于吸烟率上升和医疗保健支出增加，亚太地区正在成为一个重要的市场，当地公司与全球製药公司之间的合作促进了该地区获得创新治疗方法。

肺腺癌治疗市场-竞争格局：

肺腺癌治疗市场的竞争格局的特点是北美主要参与者的重大活动，由于先进的医疗基础设施和肺癌的高盛行率，北美在市场份额方面处于领先地位。 2023年，罗氏、阿斯特捷利康等主要製药公司宣布合作，加强标靶疗法和免疫疗法的开发。例如，阿斯特捷利康推出的新药Tagrisso（奥希替尼）在治疗EGFR突变肺腺癌患者方面显示出良好的前景，使其成为肿瘤学家的首选。此外，百时美施贵宝于 2020 年底收购了 MyoKardia，使他们能够加强其肿瘤产品组合，并专注于肺癌治疗。欧洲公司也在取得长足进步，诺华公司和欧洲癌症组织最近建立了合作伙伴关係，以改善患者获得创新治疗的机会。随着竞争的加剧，正在进行的临床试验和产品创新仍然至关重要，将塑造全球肺腺癌治疗方案的未来格局。

最新进展：

2024年4月，FDA核准艾来替尼（Alecensa）作为肿瘤切除后间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌（NSCLC）患者的辅助治疗，且此病情经FDA核准的检验证实。

2024年3月，辉瑞公司公布了3期CROWN试验的长期追踪结果，该试验评估了第三代ALK抑制剂LORBRENA（lorlatinib）相对于XALKORI（crizotinib）在未经治疗的晚期患者中的疗效。变性淋巴瘤激酶(ALK) 阳性非小细胞肺癌(NSCLC)。

目录

第一章：肺腺癌治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类别分類的肺腺癌治疗市场片段
    • 按治疗类型分類的肺腺癌治疗市场片段
    • 按治疗阶段分類的肺腺癌治疗市场片段
    • 最终使用者的肺腺癌治疗市场片段
    • 各国肺腺癌治疗市场片段
    • 按地区分類的肺腺癌治疗市场片段
  • 竞争洞察

第 3 章：肺腺癌治疗主要市场趋势

  • 肺腺癌治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 肺腺癌治疗市场限制
    • 市场限制影响分析
  • 肺腺癌治疗市场机会
  • 肺腺癌治疗市场未来趋势

第 4 章：肺腺癌治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：肺腺癌治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：肺腺癌治疗市场格局

  • 2023 年肺腺癌治疗市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：肺腺癌治疗市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • EGFR抑制剂
    • ALK 抑制剂
    • PD-1/PD-L1 抑制剂
    • 血管内皮生长因子抑制剂

第 8 章：肺腺癌治疗市场 - 依治疗类型

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 化疗
    • 标靶治疗
    • 免疫疗法
    • 联合疗法

第 9 章：肺腺癌治疗市场 - 按治疗阶段

  • 概述
    • 按治疗阶段分類的细分市场占有率分析
    • 早期腺癌
    • 晚期或转移性腺癌

第 10 章：肺腺癌治疗市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 肿瘤科诊所
    • 研究机构

第 11 章：肺腺癌治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美肺腺癌治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按治疗类型）
    • 北美市场规模与预测（按治疗阶段）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲肺腺癌治疗主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模和预测（按治疗类型）
    • 欧洲市场规模与预测（按治疗阶段）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区肺腺癌治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（按治疗类型）
    • 亚太地区市场规模与预测（依治疗阶段）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲肺腺癌治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按治疗类型）
    • 拉丁美洲市场规模与预测（按治疗阶段）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲肺腺癌治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模和预测（按治疗类型）
    • 中东和非洲市场规模及预测（依治疗阶段）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章：主要供应商分析-肺腺癌治疗产业

  • 竞争仪表板
  • 公司简介
    • Amgen Inc.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Genentech, Inc. (Roche)
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Janssen Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4114

REPORT HIGHLIGHT

Lung Adenocarcinoma Treatment Market size was valued at USD 5,512.09 Million in 2023, expanding at a CAGR of 10.70% from 2024 to 2032.

The Lung Adenocarcinoma Treatment Market encompasses therapies specifically aimed at treating lung adenocarcinoma, a common subtype of non-small cell lung cancer. With rising global incidences, attributed to increased smoking rates and environmental factors, the market is witnessing significant growth. According to the American Cancer Society, approximately 236,000 new cases of lung cancer are expected in the U.S. in 2023, with adenocarcinoma accounting for nearly 40% of those cases. Advances in targeted therapies, such as epidermal growth factor receptor (EGFR) inhibitors and anaplastic lymphoma kinase (ALK) inhibitors, are enhancing treatment options, while immunotherapy is gaining traction for its effectiveness in advanced stages. However, challenges such as high treatment costs and adverse side effects may hinder market expansion. Nevertheless, ongoing research and development initiatives aimed at improving existing therapies and the emergence of personalized medicine present substantial opportunities for market players, fostering innovations that could transform patient outcomes in lung adenocarcinoma treatment.

Lung Adenocarcinoma Treatment Market- Market Dynamics

Rising Smoking Rates Fuel Growth in the Lung Adenocarcinoma Treatment Market

The escalating rates of smoking worldwide significantly contribute to the growth of the Lung Adenocarcinoma Treatment Market, as smoking is a primary risk factor for lung cancer. The World Health Organization (WHO) estimates that over 1.3 billion people are currently smokers, with tobacco use accounting for nearly 22% of cancer-related deaths globally. In the United States, the Centers for Disease Control and Prevention (CDC) reports that lung cancer is the leading cause of cancer mortality, with smoking responsible for approximately 85% of cases. As public awareness campaigns increase and smoking cessation programs are implemented, the demand for effective treatments is anticipated to rise. Pharmaceutical companies are responding to this trend by investing in innovative therapies, including targeted treatments and immunotherapies, to address the growing patient population. Additionally, initiatives from organizations like the American Lung Association aim to reduce smoking prevalence and improve early diagnosis, further driving the need for advanced treatment options in the lung adenocarcinoma sector.

Lung Adenocarcinoma Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.70% over the forecast period (2024-2032)

Based on Drug Class segmentation, EGFR Inhibitors were predicted to show maximum market share in the year 2023

Based on Therapy Type segmentation, Targeted Therapy was the leading type in 2023

Based on Stage of Treatment segmentation, Advanced or Metastatic Adenocarcinoma was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Lung Adenocarcinoma Treatment Market- Segmentation Analysis:

The Global Lung Adenocarcinoma Treatment Market is segmented on the basis of Drug Class, Therapy Type, Stage of Treatment, End-User, and Region.

The market is divided into four categories based on Drug Class: EGFR Inhibitors, ALK Inhibitors, PD-1/PD-L1 Inhibitors, and VEGF Inhibitors. EGFR Inhibitors hold the highest priority due to their effectiveness in targeting specific mutations. ALK Inhibitors follow, offering targeted therapy for ALK-positive patients, while PD-1/PD-L1 Inhibitors and VEGF Inhibitors provide additional treatment options.

The market is divided into four categories based on Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Combination Therapy. Targeted therapy ranks highest due to its precision in addressing specific cancer mutations. Immunotherapy follows, leveraging the immune system to combat cancer. Combination therapy is gaining traction, while chemotherapy remains a standard but less prioritized option.

Lung Adenocarcinoma Treatment Market- Geographical Insights

North America is a leading region in the Lung Adenocarcinoma Treatment Market, primarily due to high incidences of lung cancer and advanced healthcare infrastructure. According to the American Cancer Society, lung cancer is expected to account for about 25% of all cancer deaths in the U.S. in 2023. In 2022, the U.S. Food and Drug Administration (FDA) approved a new combination therapy of nivolumab and ipilimumab for patients with advanced lung adenocarcinoma, highlighting the ongoing innovation in treatment options. Europe follows closely, with countries like Germany and the UK increasing investment in lung cancer research and personalized medicine approaches. The European Society for Medical Oncology (ESMO) reports a growing emphasis on targeted therapies, supported by initiatives aimed at early detection and prevention. Meanwhile, Asia-Pacific is emerging as a significant market due to rising smoking rates and increasing healthcare expenditure, with collaborations between local firms and global pharmaceutical companies facilitating access to innovative treatments across the region.

Lung Adenocarcinoma Treatment Market- Competitive Landscape:

The competitive landscape of the Lung Adenocarcinoma Treatment Market is characterized by significant activities from key players in North America, which leads in market share due to advanced healthcare infrastructure and a high prevalence of lung cancer. In 2023, major pharmaceutical companies such as Roche and AstraZeneca announced collaborations to enhance the development of targeted therapies and immunotherapies. For instance, AstraZeneca's launch of its new drug, Tagrisso (osimertinib), has shown promise in treating patients with EGFR-mutated lung adenocarcinoma, making it a preferred choice among oncologists. Additionally, Bristol-Myers Squibb's acquisition of MyoKardia in late 2020 has enabled them to bolster their oncology portfolio, focusing on lung cancer therapies. European companies are also making strides, with a recent partnership between Novartis and the European Cancer Organization to improve patient access to innovative treatments. As competition intensifies, ongoing clinical trials and product innovations remain critical, shaping the future landscape of lung adenocarcinoma treatment options globally.

Recent Developments:

In April 2024, the FDA approved alectinib (Alecensa) as an adjuvant treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following tumor resection, with the condition confirmed by an FDA-approved test.

In March 2024, Pfizer Inc. announced the long-term follow-up results from the Phase 3 CROWN trial, which assessed the efficacy of LORBRENA (lorlatinib), a third-generation ALK inhibitor, against XALKORI (crizotinib) in patients with untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Genentech, Inc. (Roche)
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Others

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • EGFR Inhibitors
  • ALK Inhibitors
  • PD-1/PD-L1 Inhibitors
  • VEGF Inhibitors

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Combination Therapy

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY STAGE OF TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Early-Stage Adenocarcinoma
  • Advanced or Metastatic Adenocarcinoma

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Oncology Clinics
  • Research Institutions

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Lung Adenocarcinoma Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Lung Adenocarcinoma Treatment Market Snippet by Drug Class
    • 2.1.2. Lung Adenocarcinoma Treatment Market Snippet by Therapy Type
    • 2.1.3. Lung Adenocarcinoma Treatment Market Snippet by Stage of Treatment
    • 2.1.4. Lung Adenocarcinoma Treatment Market Snippet by End-User
    • 2.1.5. Lung Adenocarcinoma Treatment Market Snippet by Country
    • 2.1.6. Lung Adenocarcinoma Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Lung Adenocarcinoma Treatment Key Market Trends

  • 3.1. Lung Adenocarcinoma Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Lung Adenocarcinoma Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Lung Adenocarcinoma Treatment Market Opportunities
  • 3.4. Lung Adenocarcinoma Treatment Market Future Trends

4. Lung Adenocarcinoma Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Lung Adenocarcinoma Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Lung Adenocarcinoma Treatment Market Landscape

  • 6.1. Lung Adenocarcinoma Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Lung Adenocarcinoma Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. EGFR Inhibitors
    • 7.1.3. ALK Inhibitors
    • 7.1.4. PD-1/PD-L1 Inhibitors
    • 7.1.5. VEGF Inhibitors

8. Lung Adenocarcinoma Treatment Market - By Therapy Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
    • 8.1.2. Chemotherapy
    • 8.1.3. Targeted Therapy
    • 8.1.4. Immunotherapy
    • 8.1.5. Combination Therapy

9. Lung Adenocarcinoma Treatment Market - By Stage of Treatment

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Stage of Treatment, 2023 & 2032 (%)
    • 9.1.2. Early-Stage Adenocarcinoma
    • 9.1.3. Advanced or Metastatic Adenocarcinoma

10. Lung Adenocarcinoma Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Oncology Clinics
    • 10.1.4. Research Institutions

11. Lung Adenocarcinoma Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Lung Adenocarcinoma Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Lung Adenocarcinoma Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Lung Adenocarcinoma Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Lung Adenocarcinoma Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Lung Adenocarcinoma Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Lung Adenocarcinoma Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Amgen Inc.
    • 12.2.2. Astellas Pharma Inc.
    • 12.2.3. AstraZeneca PLC
    • 12.2.4. Bayer AG
    • 12.2.5. Boehringer Ingelheim GmbH
    • 12.2.6. Bristol-Myers Squibb Company
    • 12.2.7. Eli Lilly and Company
    • 12.2.8. Genentech, Inc. (Roche)
    • 12.2.9. Gilead Sciences, Inc.
    • 12.2.10. GlaxoSmithKline plc
    • 12.2.11. Janssen Pharmaceuticals, Inc.
    • 12.2.12. Merck & Co., Inc.
    • 12.2.13. Novartis AG
    • 12.2.14. Pfizer Inc.
    • 12.2.15. Sanofi S.A.
    • 12.2.16. Takeda Pharmaceutical Company Limited
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us